Cardiovascular News’ top 10 most popular stories of August 2022

476

The most read stories from across Cardiovascular News in August 2022 include highlights from the European Society of Cardiology (ESC) 2022 annual congress (26–29 August, Barcelona, Spain), new developments in coronary stent technology, and projections of a “worrisome” rise in cardiovascular disease out to 2060.

  1. REVIVED data show PCI does not benefit patients with severe left ventricular dysfunction
    Percutaneous coronary intervention (PCI) does not reduce all-cause mortality or heart failure hospitalisation in patients with severe left ventricular dysfunction and extensive coronary artery disease, late-breaking research presented at ESC 2022 has shown.
  2. Medtronic launches Onyx Frontier coronary stent following CE mark approval
    Medtronic has announced the launch of its latest generation drug-eluting coronary stent—Onyx Frontier—following recent CE mark approval.
  3. Spotlight turns to TAVI in patients with moderate aortic stenosis
    Ongoing clinical trials looking at transcatheter aortic valve implantation (TAVI) for patients with moderate aortic stenosis could lead to an expansion of indications for current TAVI platforms to include many patients currently outside of the scope of the therapy.
  4. Cardiac surgeons among signatories to group seeking “critical appraisal” of evidence in cardiovascular medicine
    Cardiac surgeons from North America, Europe and Latin America are among the signatories to a multidisciplinary group seeking to address what it describes as a “widening gap” between evidence and guideline recommendations in cardiovascular medicine.
  5. SECURE trial finds “polypill” results in lower risk of cardiovascular events compared to usual care
    Use of a ‘polypill’ after myocardial infarction (MI)—an all-in-one pill containing an antiplatelet, lipid lowering medication, and a blood pressure lowering and vascular stabilising drug—was found to be more effective at reducing the risk of major adverse cardiovascular events than when patients were asked to take the medications separately.
  6. FRAME-AMI sheds light on best strategy for selecting non-infarct lesions for PCI
    Selection of non-infarct related artery (IRA) lesions for intervention using fractional flow reserve (FFR) is superior to routine angiography-based selection in patients with acute myocardial infarction and multivessel disease, researchers have reported.
  7. “Worrisome” rise in cardiovascular disease predicted out to 2060
    Projected rates of cardiovascular risk factors and disease will increase significantly in the USA by 2060, a study published in the Journal of the American College of Cardiology (JACC) has claimed.
  8. Timing of antihypertensive medication “makes no difference” to cardiovascular outcomes
    The timing of dosing of antihypertensive medication—whether it is taken in the morning or in the evening—does not have a bearing on cardiovascular outcomes, randomised trial results presented during a hot line session at the ESC annual congress indicate.
  9. Edwards gains CE mark for Pascal Precision system for mitral and tricuspid regurgitation
    Edwards Lifesciences has announced that the company’s Pascal Precision transcatheter valve repair system received CE mark for the treatment of mitral and tricuspid regurgitation (MR and TR).
  10. MASTER DAPT continues to show merit for shortened dual antiplatelet therapy out to 15 months post-PCI
    Fifteen-month results from the MASTER DAPT trial have shown that the preserved ischaemic benefits and reduced bleeding risk seen with one month of dual antiplatelet therapy (DAPT) among high-bleeding risk patients undergoing percutaneous coronary intervention (PCI) continue beyond one year.

LEAVE A REPLY

Please enter your comment!
Please enter your name here